Elite Pharmaceuticals, Inc., a company develops oral sustained and controlled release products,  has started shipment of Phendimetrazine tartrate 35 mg tablets, the generic equivalent of Bontril PDM 35 mg tablets under the previously announced manufacturing and supply agreement with Mikah Pharma.

Actavis, Inc. recently acquired by Watson Pharmaceuticals Inc., will distribute the product as part of a distribution agreement between Mikah and Actavis.

Bontril PDM and its generic equivalents had total US sales of approximately $3.5 million for the twelve months ending September 2012 based on IMS Health Data. Elite will be compensated at an agreed upon price for the manufacturing and packaging of the product.

“The manufacture of PDM by Elite for Mikah and its subsequent distribution by Actavis/Watson represents another example of the Company’s strategy for enhancing our generic pipeline and cash flow,” commented Jerry Treppel, chairman and CEO.